228 related articles for article (PubMed ID: 24842651)
1. Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Konieczny J; Jantas D; Lenda T; Domin H; Czarnecka A; Kuter K; Śmiałowska M; Lasoń W; Lorenc-Koci E
Neurotox Res; 2014 Oct; 26(3):255-73. PubMed ID: 24842651
[TBL] [Abstract][Full Text] [Related]
2. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
3. Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Konieczny J; Czarnecka A; Kamińska K; Lenda T; Nowak P
Behav Brain Res; 2015 Apr; 283():203-14. PubMed ID: 25655509
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
Li C; Guo Y; Xie W; Li X; Janokovic J; Le W
Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141
[TBL] [Abstract][Full Text] [Related]
5. The extent of neurodegeneration and neuroprotection in two chemical in vitro models related to Parkinson's disease is critically dependent on cell culture conditions.
Jantas D; Roman A; Kuśmierczyk J; Lorenc-Koci E; Konieczny J; Lenda T; Lasoń W
Neurotox Res; 2013 Jul; 24(1):41-54. PubMed ID: 23307753
[TBL] [Abstract][Full Text] [Related]
6. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
7. Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Konieczny J; Lenda T; Czarnecka A
Neuroscience; 2016 Jun; 324():92-106. PubMed ID: 26964686
[TBL] [Abstract][Full Text] [Related]
8. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
Li C; Biswas S; Li X; Dutta AK; Le W
J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
[TBL] [Abstract][Full Text] [Related]
9. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.
Wąsik A; Romańska I; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
Neurotox Res; 2018 Oct; 34(3):706-716. PubMed ID: 30129004
[TBL] [Abstract][Full Text] [Related]
10. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W
FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154
[TBL] [Abstract][Full Text] [Related]
11. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
12. Novel 1-hydroxypyridin-2-one metal chelators prevent and rescue ubiquitin proteasomal-related neuronal injury in an in vitro model of Parkinson's disease.
Lewis FW; Fairooz S; Elson JL; Hubscher-Bruder V; Brandel J; Soundararajan M; Smith D; Dexter DT; Tétard D; Pienaar IS
Arch Toxicol; 2020 Mar; 94(3):813-831. PubMed ID: 32078022
[TBL] [Abstract][Full Text] [Related]
13. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Antkiewicz-Michaluk L
Neuroscience; 2017 Jan; 340():308-318. PubMed ID: 27826109
[TBL] [Abstract][Full Text] [Related]
14. Adaptive changes in autophagy after UPS impairment in Parkinson's disease.
Shen YF; Tang Y; Zhang XJ; Huang KX; Le WD
Acta Pharmacol Sin; 2013 May; 34(5):667-73. PubMed ID: 23503475
[TBL] [Abstract][Full Text] [Related]
15. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
16. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W
Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853
[TBL] [Abstract][Full Text] [Related]
17. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity.
Cleren C; Calingasan NY; Chen J; Beal MF
J Neurochem; 2005 Aug; 94(4):995-1004. PubMed ID: 16092942
[TBL] [Abstract][Full Text] [Related]
18. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
[TBL] [Abstract][Full Text] [Related]
19. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition.
Fornai F; Lenzi P; Gesi M; Ferrucci M; Lazzeri G; Busceti CL; Ruffoli R; Soldani P; Ruggieri S; Alessandri MG; Paparelli A
J Neurosci; 2003 Oct; 23(26):8955-66. PubMed ID: 14523098
[TBL] [Abstract][Full Text] [Related]
20. Caloric Restriction Protects against Lactacystin-Induced Degeneration of Dopamine Neurons Independent of the Ghrelin Receptor.
Coppens J; Bentea E; Bayliss JA; Demuyser T; Walrave L; Albertini G; Van Liefferinge J; Deneyer L; Aourz N; Van Eeckhaut A; Portelli J; Andrews ZB; Massie A; De Bundel D; Smolders I
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
